23andMe (NASDAQ:ME) Earns “Sell (E+)” Rating from Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating reissued by analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

23andMe Stock Performance

Shares of NASDAQ:ME opened at $3.61 on Friday. 23andMe has a 1-year low of $2.65 and a 1-year high of $16.52. The stock has a market capitalization of $94.29 million, a P/E ratio of -0.14 and a beta of 1.14. The business has a 50-day moving average price of $3.51 and a two-hundred day moving average price of $5.63.

23andMe (NASDAQ:ME) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter. The business had revenue of $44.07 million for the quarter, compared to analyst estimates of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC raised its stake in shares of 23andMe by 410.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock worth $35,000 after purchasing an additional 71,204 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in 23andMe in the second quarter valued at $43,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of 23andMe in the 2nd quarter valued at about $203,000. AQR Capital Management LLC increased its stake in shares of 23andMe by 145.8% during the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock worth $174,000 after purchasing an additional 263,468 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of 23andMe in the 3rd quarter valued at about $805,000. 36.10% of the stock is currently owned by institutional investors.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.